Farnaz Tabatabaian, MD, MS, associate professor, Division of Allergy & Immunology, Department of Internal Medicine, USF Health Morsani College of Medicine, provides background on mast cell biology and discusses mastocytosis presentation. Dr Tabatabaian also reviews current and emerging therapeutic options for patients.
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
John M. Fahrenholz, MD, Vanderbilt University Medical Center, Nashville, Tennessee, discusses questions about nonadvanced systemic mastocytosis submitted by participants. Topics include triggers for mast cell activation, management strategies…
Presented by the Florida Society of Clinical Oncology, this program provides opportunities for patients and caregivers to learn and share information regarding a diagnosis of systemic mastocytosis. Pankit…
In an interview conducted at the 2025 European Society for Blood and Marrow Transplantation Annual Meeting, Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St…
Systemic mastocytosis, a rare blood disorder, affects the entire body. There are many challenges associated with living with this systemic mastocytosis that are centered around reducing the frequency…
